Richard Blackmore, Ph.D.

Dr. Blackmore has over 27 years of experience in development of fermentation, purification, and chemical modification processes for human therapeutic proteins.  He has extensive experience in cGMP manufacturing support, scale-down process modeling, computer-based monitoring and control and technology transfer.  Dr. Blackmore has particular skills in mathematical modelling of biological processes and in Exploratory Data Analysis. Dr. Blackmore's career started at Baxter/Somatogen where he developed fermentation and purification processes for various products and managed the R&D fermentation facility.  He then proceeded to Seattle Genetics where he developed and scaled up processes for monoclonal antibodies and Antibody Drug Conjugates.  Subsequently Dr. Blackmore spent time at Emergent Biosolutions/Trubion where he gained experience on mono and bi-specific mAb-like bio-pharmaceuticals based on scFv fragments.  Dr. Blackmore has also spent a number of years at Dendreon where he has managed upstream and downstream development organizations for antigen development as well as technical support for CMO operations and the Process Monitoring Program for Dendron’s Autologous Cellular Immunotherapy (Provenge™).  Dr. Blackmore holds a Ph.D. in Biological Sciences from University of East Anglia, Norwich, U.K. and was a Postdoctoral Fellow at Cornell University, Ithaca, NY.